Cantor Fitzgerald Issues Positive Estimate for FDMT Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Analysts at Cantor Fitzgerald upped their FY2025 earnings estimates for 4D Molecular Therapeutics in a report released on Tuesday, March 4th. Cantor Fitzgerald analyst J. Schimmer now expects that the company will earn ($3.22) per share for the year, up from their prior forecast of ($3.46). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share.

FDMT has been the topic of several other reports. Bank of America decreased their price target on shares of 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. BMO Capital Markets lowered shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $40.00 to $15.00 in a research report on Monday, January 13th. Leerink Partners cut their price objective on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating for the company in a research report on Monday, January 13th. Chardan Capital reduced their price objective on 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Morgan Stanley cut their price objective on shares of 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $31.38.

4D Molecular Therapeutics Stock Down 0.5 %

Shares of FDMT stock opened at $4.14 on Thursday. The company has a market cap of $191.69 million, a PE ratio of -1.45 and a beta of 2.83. 4D Molecular Therapeutics has a 12 month low of $3.92 and a 12 month high of $36.25. The business’s 50 day moving average is $5.08 and its two-hundred day moving average is $8.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10).

Institutional Trading of 4D Molecular Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Decheng Capital LLC raised its stake in 4D Molecular Therapeutics by 0.5% during the 4th quarter. Decheng Capital LLC now owns 400,000 shares of the company’s stock worth $2,228,000 after buying an additional 2,165 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of 4D Molecular Therapeutics by 7.1% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company’s stock worth $247,000 after purchasing an additional 2,925 shares during the period. PNC Financial Services Group Inc. raised its position in 4D Molecular Therapeutics by 66.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after acquiring an additional 3,630 shares during the period. Rhumbline Advisers lifted its stake in 4D Molecular Therapeutics by 5.3% in the fourth quarter. Rhumbline Advisers now owns 73,431 shares of the company’s stock valued at $409,000 after purchasing an additional 3,675 shares during the last quarter. Finally, ProShare Advisors LLC lifted its position in shares of 4D Molecular Therapeutics by 30.1% during the 4th quarter. ProShare Advisors LLC now owns 16,369 shares of the company’s stock valued at $91,000 after buying an additional 3,783 shares during the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.